Magellan Midstream Partners LP
Change company Symbol lookup
Select an option...
MMP Magellan Midstream Partners LP
ELTK Eltek Ltd
LE Lands End Inc
WING Wingstop Inc
PUMP ProPetro Holding Corp
CHK Chesapeake Energy Corp
SALM Salem Media Group Inc
UGAZ VelocityShares 3x Long Natural Gas ETN Linked to the S&P GSCI? Natural Gas Index ER
UBSI United Bankshares Inc
LTM LATAM Airlines Group SA
Go

Energy : Oil, Gas & Consumable Fuels | Mid Cap Value
Company profile

Magellan Midstream Partners, L.P. is principally engaged in the transportation, storage and distribution of refined petroleum products and crude oil. The Company operates through three segments: refined products, crude oil and marine storage. As of December 31, 2016, its asset portfolio, including the assets of its joint ventures, consisted of its refined products segment, consisting 9,700-mile refined products pipeline system with 53 terminals, as well as 26 independent terminals not connected to its pipeline system and its 1,100-mile ammonia pipeline system; its crude oil segment, consisted of approximately 2,200 miles of crude oil pipelines and storage facilities with an aggregate storage capacity of approximately 26 million barrels, of which 16 million are used for contract storage, and its marine storage segment, consisted of five marine terminals located along coastal waterways with an aggregate storage capacity of approximately 26 million barrels.

Closing Price
$44.53
Day's Change
-0.81 (-1.79%)
Bid
--
Ask
--
B/A Size
--
Day's High
45.57
Day's Low
44.35
Volume
(Light)
Volume:
780,123

10-day average volume:
1,009,619
780,123

UPDATE: These 23 companies are working on coronavirus treatments or vaccines -- here's where things stand

12:02 pm ET May 16, 2020 (MarketWatch)
Print

By Jaimy Lee

The list includes Gilead Sciences and Moderna, alongside smaller biotech companies

A mix of legacy drug makers and small startups have stepped forward with plans to develop vaccines or treatments that target the infection caused by the novel coronavirus.

COVID-19, which was first detected in December in Wuhan, China (http://www.marketwatch.com/story/the-coronavirus-from-wuhan-china-now-has-a-name-covid-19-2020-02-11), has since sickened nearly 4.6 million people worldwide and killed more than 300,000, (http://www.marketwatch.com/story/covid-19-case-tally-457-million-cases-30843-deaths-as-russia-sees-big-overnight-spike-in-infections-2020-05-16) (http://www.marketwatch.com/story/covid-19-case-tally-457-million-cases-30843-deaths-as-russia-sees-big-overnight-spike-in-infections-2020-05-16) as of mid-May.

The Food and Drug Administration has issued two emergency-use authorizations for COVID-19 treatments, including one for hydroxychloroquine sulfate and chloroquine phosphate (http://www.marketwatch.com/story/theres-scant-evidence-for-chloroquine-so-far-as-a-covid-19-drug-but-theres-already-a-shortage-2020-03-30) in March to treat COVID-19 patients and one for Gilead Sciences Inc.'s remdesivir (http://www.marketwatch.com/story/how-gileads-remdesivir-became-the-leader-in-the-rush-to-find-a-treatment-for-covid-19-2020-05-01) on May 1. No drugs or vaccines have received FDA approval.

Read more of MarketWatch's coverage of COVID-19 (http://www.marketwatch.com/economy-politics/coronavirus).

In the U.S., many of the publicly traded companies that are initiating development have received funding from two organizations: the Biomedical Advanced Research and Development Authority, or BARDA, which is a division of the Department of Health and Human Services, and the National Institute of Allergy and Infectious Diseases, or NIAID, a division of the National Institutes of Health. Some companies have also received funding from Coalition for Epidemic Preparedness Innovations, or CEPI, a global organization based in Oslo that has provided millions of dollars in funding to vaccine makers. Other companies are funding trials by themselves or through life-sciences-company partnerships.

These are some of the companies developing treatments or vaccines in the U.S. for COVID-19, as of early May. (An earlier version of the article included several adjuvant platform technologies that are used to aid the development process and a privately held company, but they have since been removed to focus on public companies.)

Amgen and Adaptive Biotechnologies

Type: Antibody treatment

Stage: Preclinical

Background: The very early-stage collaboration between Amgen Inc. (AMGN) and Adaptive Biotechnologies Corp. (ADPT) seeks to discover antibodies that can be used to prevent or treat COVID-19. Financial terms of the exclusive collaboration will be completed "in the coming weeks," the companies said April 2 (). "There may well be more than one generation of antibody therapeutics entering the clinic," Amgen R&D EVP David Reese told investors on an earnings call.

Also in the works: Amgen will test Otezla as a COVID-19 therapy treating respiratory distress in late-stage patients, with the company saying April 30 that it plans to put the oral psoriasis drug into trials "in the coming weeks."

Year-to-date stock performance: Amgen's stock is down 1.9%; Adaptive's is up 10.3%.

Altimmune

Type: Vaccine

Stage: Preclinical

Name: AdCOVID

Background: Altimmune Inc. (ALT) said March 30 it is partnering with University of Alabama at Birmingham to develop a single-dose, intranasal COVID-19 vaccine. They said they plan to put the vaccine candidate into Phase 1 trials in the third quarter. The preclinical company is also developing vaccines for anthrax and the flu.

Year-to-date stock performance: Shares of Altimmune have gone up 60.8%.

BioNTech and Pfizer

Type: mRNA vaccine

Stage: Phase 1/2

Name: BNT162 program

Background: Pfizer Inc. (PFE) announced (http://www.marketwatch.com/story/biontech-pfizer-to-develop-covid-19-vaccine-candidate-2020-03-17) March 17 it would help develop and distribute BioNTech SE's (BNTX) COVID-19 vaccine candidate, though the deal excludes China. The 360 patients in the U.S. trial (https://clinicaltrials.gov/ct2/show/NCT04368728?term=BNT162+covid&draw=2&rank=1) had started to receive the first doses (http://www.marketwatch.com/story/biontech-pfizer-stocks-rally-after-first-participants-in-us-trial-of-covid-19-vaccine-were-dosed-2020-05-05) of the four vaccine candidates included in the study as of May 5. Dosing in 200 participants in the German trial began April 23. As part of the deal, Pfizer will pay $185 million upfront (http://www.marketwatch.com/story/pfizer-discloses-185-million-upfront-payment-to-biontech-for-covid-19-vaccine-program-2020-04-09), with additional possible future milestone payments of up to $563 million. Mikael Dolsten, Pfizer's chief scientific officer, said during an April 28 earnings call that the companies expect the first round of trial data in May or June, with the vaccine candidate moving into "expanded trials that could allow emergency use or accelerated approval coming in the fall, possibly October."

BioNTech is also testing the vaccine in collaboration with Shanghai Fosun Pharmaceutical Group Co. Ltd. in China.

Pfizer and BioNTech for several years have said they are working on mRNA-based influenza vaccines.

Year-to-date stock performances: Shares of BioNTech have soared 47.6%; Pfizer's stock is down 1.7%.

CytoDyn

Type: Treatment

Stage: Phase 2 and Phase 2b/3 clinical trials

Name: leronlimab

Background: CytoDyn Inc. (CYDY), a preclinical biotechnology company based in Vancouver, is testing (http://www.marketwatch.com/story/cytodyn-moves-forward-with-mid-stage-trial-for-experimental-covid-19-treatment-2020-03-31) its experimental drug leronlimab in two types of COVID-19 patients. The investigational therapy hasn't been approved for any indications; for COVID-19, it is being proposed as a treatment for mild-to-moderate (https://clinicaltrials.gov/ct2/show/NCT04343651?term=leronlimab+covid&draw=2&rank=2) respiratory complications that occur in patients with the disease as well as severely and critically ill patients (https://clinicaltrials.gov/ct2/show/NCT04347239?term=leronlimab+covid&draw=2&rank=1).

The randomized, double-blind, placebo-controlled study will test the efficacy and safety of leronlimab in 75 patients. CytoDyn had been studying the experimental therapy as a treatment for people with HIV and a form of metastatic breast cancer.

Year-to-date stock performance: CytoDyn's stock has soared 213.0%.

Gilead Sciences

Type: Treatment

Stage: Emergency use authorization

Name: remdesivir

Background: Gilead Sciences Inc. (GILD) is a longtime drugmaker best known for developing the first major cure for hepatitis-C in Sovaldi, a therapy that changed the standard of care for that disease but also kicked off the national debate about drug pricing. The company has experience developing and marketing HIV drugs, including Truvada for pre-exposure prophylaxis (PrEP), its preventive HIV medicine.

It received an emergency-use authorization (http://www.marketwatch.com/story/how-gileads-remdesivir-became-the-leader-in-the-rush-to-find-a-treatment-for-covid-19-2020-05-01) from the Food and Drug Administration in the U.S. on May 1 based on preliminary results from two clinical trials: one conducted by the NIAID, and one by Gilead. In the NIAID trial, COVID-19 patients taking the drug had a median recovery time of 11 days, compared with 15 days for those patients taking placebo. NIAID director Dr. Anthony Fauci has said the drug is now considered the standard of care; however, other experts have had mixed responses to the data. Dr. Eric Topol, director of the Scripps Research Translational Institute, said he thinks the drug is effective based on the preliminary data that has been made public. "It's just not that potent," he said via email.

The drug was also used in two randomized, controlled clinical trials in China. Results from one trial, which was stopped early, found the drug didn't produce "statistically significant clinical benefits," according to findings published in The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31022-9/fulltext?mod=article_inline&mod=article_inline).

Gilead in late March had to halt individual compassionate use requests (http://www.marketwatch.com/story/gilead-sciences-flooded-by-demand-for-redesivir-halts-compassionate-use-2020-03-23) for remdesivir as outbreaks worsened in the U.S., having provided the investigational therapy to 1,000 patients. "The system cannot support and process the overwhelming number of applications we have seen with COVID-19," Gilead CEO Daniel O'Day said March 28.

The company told investors on May 1 it may spend up to $1 billion this year to develop and manufacture remdesivir, and it aims to have 500,000 treatment courses by October and 1 million by the end of 2020.

Gilead's notable clinical trials:

1. The National Institute of Allergy and Infectious Diseases trial has enrolled patients in a randomized, double-blind, placebo-controlled Phase 3 trial (https://clinicaltrials.gov/ct2/show/NCT04280705) evaluating 1,063 hospitalized patients with COVID-19 at 68 sites worldwide, including at three sites in Singapore and South Korea, according to the NIAID. However, the majority of the study locations are in the U.S. The study began Feb. 21 and is expected to conclude April 1, 2023. Preliminary results from this trial were used to inform the EUA.

(MORE TO FOLLOW) Dow Jones Newswires

May 16, 2020 12:02 ET (16:02 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.